Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

2/20/25 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CRDF alert in real time by email

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024.

Conference Call and Webcast

Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company's website following the completion of the call.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:

James Levine

Chief Financial Officer

858-952-7670

[email protected]

Investor Contact:

Kiki Patel, PharmD

Gilmartin Group

332-895-3225

[email protected]

Media Contact:

Grace Spencer

Taft Communications

609-583-1151

[email protected]

Get the next $CRDF alert in real time by email

Date	Price Target	Rating	Analyst
9/6/2024	$8.00	Buy	Craig Hallum
2/28/2022	$26.00 → $25.00	Buy	HC Wainwright & Co.
1/5/2022		Outperform	William Blair
12/8/2021	$19.00	Outperform	Robert W. Baird
12/8/2021	$19.00	Outperform	Baird
8/10/2021	$25.00 → $26.00	Buy	HC Wainwright & Co.
8/9/2021	$30.00 → $20.00	Buy	Maxim Group

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Chat with this insight

Recent Analyst Ratings for
$CRDF

$CRDF
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Levine James E. bought $36,726 worth of shares (7,716 units at $4.76) (SEC Form 4)

Director Tannenbaum Renee P bought $34,224 worth of shares (10,000 units at $3.42), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

Director Pace Gary W bought $940,199 worth of shares (361,615 units at $2.60), increasing direct ownership by 50% to 1,047,876 units (SEC Form 4)

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Chat with this insight

Recent Analyst Ratings for $CRDF

$CRDF Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Levine James E. bought $36,726 worth of shares (7,716 units at $4.76) (SEC Form 4)

Director Tannenbaum Renee P bought $34,224 worth of shares (10,000 units at $3.42), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

Director Pace Gary W bought $940,199 worth of shares (361,615 units at $2.60), increasing direct ownership by 50% to 1,047,876 units (SEC Form 4)

Recent Analyst Ratings for
$CRDF

$CRDF
Insider Purchases